Quantum BioPharma (NASDAQ: QNTM) has entered a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302, or Lucid-MS, for multiple sclerosis. The agreement, reported by NEWMEDIAWIRE, initiates formal start-up activities after the U.S. Food and Drug Administration cleared the company to proceed with the trial. Thermo Fisher will provide study start-up and related clinical research services through its PPD Clinical Research Business.
The move matters because it transitions Lucid-MS from preclinical promise to a rigorously designed human study in progressive forms of MS, a condition with limited treatment options and no approved therapies that directly target the underlying mechanism of myelin degradation. The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS using clinical and radiological endpoints. If successful, the trial could validate a novel approach that not only manages symptoms but potentially protects nerve fibers from further damage.
Lucid-MS is an investigational, first-in-class new chemical entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, the compound has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. This mechanism distinguishes Lucid-MS from existing MS therapies, which largely modulate the immune system rather than directly promote myelin repair. A positive Phase 2 readout could therefore open a new therapeutic category for progressive MS, where current options are especially scarce.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS as its lead compound. The company describes itself as a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The Phase 2 trial represents a pivotal test of that strategy, with Thermo Fisher’s involvement lending operational scale and regulatory experience to the program. Investors and industry observers will be watching whether the trial can replicate the preclinical findings in people, a crucial step for any first-in-class candidate.
For those tracking the company’s progress, the full press release is available at https://ibn.fm/CZH9U, and the latest news and updates relating to QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM. Additional information on Quantum BioPharma is accessible through its Quantum BioPharma (NASDAQ: QNTM) profile. The agreement does not guarantee trial success, but it signals that the program is advancing on schedule and with a major contract research partner, which may reduce execution risk and strengthen the company’s position as it seeks to address a significant unmet need in multiple sclerosis.
